Benefit Plans (Tables)

9 Months Ended

Mar. 31, 2020

Benefit Plans

Schedule of changes in the number of shares available for grant under equity incentive plans

	Number of Shares
Available for grant at July 1, 2019	9,759
RSUs granted	(642)
Shares withheld in settlement of taxes and/or exercise price	321
Forfeitures	93
Shares removed	(39)
Available for grant at March 31, 2020	9,492

Schedule of stock-based compensation expense related to stock options, restricted stock units and the Employee Stock Purchase Plan

	Three Months Ended March 31,				Nine Months Ended March 31,
	2019		2020		2019		2020
Cost of revenues	$	1,192	$	1,362	$	3,734	$	4,057
Sales and marketing		1,799		3,466		5,496		10,813
Research and development		1,287		1,899		4,025		4,945
General and administrative		5,035		2,789		15,582		14,533
Total stock-based compensation expense	$	9,313	$	9,516	$	28,837	$	34,348

Schedule of stock option activity

	Outstanding Options
				Weighted
		Weighted		average
		average		remaining	Aggregate
	Number of	exercise		contractual	intrinsic
	shares	price		term (years)	value
Balance at July 1, 2019	1,525	$	12.24	3.95	$	124,373
Options exercised	(153)	$	11.15
Balance at March 31, 2020	1,372	$	12.37	3.20	$	104,172
Options vested and exercisable at March 31, 2020	1,372	$	12.37	3.20	$	104,172

Schedule of restricted stock unit activity

	Units	Weighted average grant date fair value
RSU balance at July 1, 2019	1,813	$	53.78
RSUs granted	642	$	99.72
RSUs vested	(708)	$	49.75
RSUs forfeited	(93)	$	59.72
RSU balance at March 31, 2020	1,654	$	73.57
RSUs expected to vest at March 31, 2020	1,442	$	71.83

Schedule of weighted average assumptions used for estimating grant date fair value of the ESPP

	Nine Months Ended
	March 31,
	2019		2020
Valuation assumptions:
Expected dividend yield	0	%	0	%
Expected volatility	33.5 - 38.3	%	38.6 - 43.3	%
Expected term (years)	0.5		0.5
Risk‑free interest rate	2.10 - 2.48	%	1.58 - 2.44	%